Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 12/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15441442 | 0.95 | NPSR1 (0.68) | TRPV4KMT2AMEN1GLAALDH1A1 | |
| SCHEMBL1066093 | 0.88 | TRPV4 (0.77) | TRPV4KMT2AALDH1A1MAPK1TDP1 | |
| SCHEMBL6455655 | 0.86 | TRPV4 (0.74) | TRPV4KMT2AALDH1A1MAPK1TDP1 | |
| SCHEMBL15441180 | 0.82 | TRPV4 (1.00) | TRPV4KMT2AALDH1A1MAPK1TDP1 | |
| SCHEMBL15441703 | 0.82 | TRPV4 (0.68) | TRPV4KMT2AALDH1A1MAPK1TDP1 | |
| SCHEMBL15386140 | 0.81 | TRPV4 (0.62) | TRPV4KMT2AALDH1A1MAPK1TDP1 | |
| SCHEMBL15386144 | 0.81 | TRPV4 (0.59) | TRPV4KMT2AMEN1GLAALDH1A1 | |
| SCHEMBL15441297 | 0.80 | MAPK1 (1.00) | TRPV4KMT2AALDH1A1MAPK1TDP1 | |
| SCHEMBL15441639 | 0.80 | ALDH1A1 (1.00) | TRPV4KMT2AALDH1A1MAPK1TDP1 | |
| SCHEMBL15441642 | 0.80 | TRPV4 (0.58) | TRPV4KMT2AMEN1GLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170065602-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | THE UNIVERSITY OF UTAH | 2017-03-09 | — | — | US | disclosed |
| US-20170065602-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | THE UNIVERSITY OF UTAH | 2017-03-09 | — | — | US | disclosed |
| US-20170065602-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | THE UNIVERSITY OF UTAH | 2017-03-09 | — | — | US | disclosed |
| US-20150133411-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | disclosed |
| US-20150133411-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | disclosed |
| US-20150133411-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | disclosed |
| US-20130303539-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-14 | — | — | US | disclosed |
| US-20130303539-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-14 | — | — | US | disclosed |
| US-20130303539-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133411-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | TRPV4, TRPV3, TRPV5 | TRPV4 1/4885KMT2A 3099/4885MEN1 3646/4885 |
| US-20130303539-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | TRPV4, TRPV3, TRPV2 | TRPV4 1/4885KMT2A 4684/4885MEN1 4076/4885 |
| US-20170065602-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | TRPV4, TRPV3, TRPV2 | TRPV4 1/4885KMT2A 4684/4885MEN1 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.